Encephalomalacia Market Structure Analysis for the Period 2019-2026

Posted by vinit sawant on February 11th, 2021

Increasing prevalence of neurological/brain disorder like epilepsy, rising need for better treatment, increasing investment of biotechnology and pharmaceutical industries in R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapid development of technology is likely to fuel the market growth during the forecast period.

The global encephalomalacia market is expected to grow at a CAGR of ~6.1% during the forecast period 2017-2023.

Cerebral softening (encephalomalacia) may be seen in a localized area of the brain depending on the cause. However, it can affect virtually any part of the brain, possibly damaging tissues of the frontal, occipital, parietal, and temporal lobe.

However, the number of hospitals has increased to a great extent, which is influencing the growth of the market positively. Moreover, increasing demand for better treatment and changing reimbursement policies have fueled the market growth. According to National Institute of Neurological Disorders and Stroke, it is estimated that 13%-16% of the United States suffer from brain disease/disorder.

The global encephalomalacia market is segmented on the basis of types, diagnosis, treatment, and end user. On the basis of the type, it is segmented into leukoencephalomalacia (encephalomalacia affecting the white matter), and polioencephalomalacia (encephalomalacia affecting the gray matter).